WINNING STRATEGIES WASHINGTON

WINNING STRATEGIES WASHINGTON filed a Q3 report for KALEO on October 20, 2026, reporting $10,000 in lobbying income.

Lobbying for KALEO · Pharmaceutical development and manufacturing

All filings by WINNING STRATEGIES WASHINGTON · Everything KALEO has reported

Amended

The filer submitted a later report covering this same period, so the amounts here have been replaced. Site totals count only the latest version. See the current filing, posted Oct 20, 2026.

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 20, 2026

Income

$10,000

What the client paid this registrant for the period.

Client based in

Virginia

Official filing document

Lobbyists on this filing 3

ROBERT ZUCKER

Previously held: LD, Rep. Rothman; LA,Rep. Evans (IL); Sen. Lautenberg
CHARLA PENN

Previously held: LA, Rep. Pascrell; SA/LC/LA, Rep. Boyd
CHELSEY PENROD HICKMAN

Previously held: CoS, LD, Rep. Kay Granger; Deputy LD, LA Sen. Larry Craig

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 3

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 5

Pharmacy

Pharmaceutical drug development, including epinephrine for anaphylaxis; drug access and affordability issues

Defense

Medical countermeasures research and development

Budget/Appropriations

Medical countermeasures research and development

Aviation/Airlines/Airports

FAA reauthorization provisions related to emergency medicine.

Health Issues

Legislation related to prescription drug prices, access to epinephrine in schools, childcare, and other community settings

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.